132 related articles for article (PubMed ID: 12773665)
1. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.
Roche-Lestienne C; Laï JL; Darré S; Facon T; Preudhomme C
N Engl J Med; 2003 May; 348(22):2265-6. PubMed ID: 12773665
[No Abstract] [Full Text] [Related]
2. [Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients].
Qin YZ; Liu YR; Li JL; Ruan GR; Zhu HH; Jiang Q; Fu JY; Lu Y; Chang Y; Li LD; Huang XJ; Chen SS; Qiu JY
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3186-9. PubMed ID: 16405837
[TBL] [Abstract][Full Text] [Related]
3. A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.
Gruber FX; Hjorth-Hansen H; Mikkola I; Stenke L; Johansen T
Leukemia; 2006 Nov; 20(11):2057-60. PubMed ID: 17008892
[No Abstract] [Full Text] [Related]
4. Treating cancer's kinase 'addiction'.
Baselga J; Arribas J
Nat Med; 2004 Aug; 10(8):786-7. PubMed ID: 15286778
[No Abstract] [Full Text] [Related]
5. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
[No Abstract] [Full Text] [Related]
6. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
7. Introduction: chronic myelogenous leukemia (CML).
Jabbour E; Kantarjian H
Semin Hematol; 2007 Jan; 44(1 Suppl 1):S1-3. PubMed ID: 17292735
[No Abstract] [Full Text] [Related]
8. [Second hematologic response and disappearance of the ABL gene mutant clone by cessation of imatinib in a CML patient with resistance to imatinib].
Murase K; Matsunaga T; Takeuchi N; Fujimi A; Takimoto R; Terui T; Hirayama Y; Niitsu Y
Rinsho Ketsueki; 2004 Sep; 45(9):1028-32. PubMed ID: 15510830
[TBL] [Abstract][Full Text] [Related]
9. Update on the use of imatinib mesylate.
Sawyers CL
Clin Adv Hematol Oncol; 2005 Oct; 3(10):757-8. PubMed ID: 16258483
[No Abstract] [Full Text] [Related]
10. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
11. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
12. [Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].
Ouyang Z; DU QF; Liu XL; Zhang S; Zhu HQ; Gong JM; Song LL; Ouyang LY; Liu Z
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):704-6. PubMed ID: 18504184
[TBL] [Abstract][Full Text] [Related]
13. Resistance and relapse with imatinib in CML: causes and consequences.
Deininger M
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S11-S21. PubMed ID: 18397677
[TBL] [Abstract][Full Text] [Related]
14. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
15. New-age drug meets resistance.
McCormick F
Nature; 2001 Jul; 412(6844):281-2. PubMed ID: 11460142
[No Abstract] [Full Text] [Related]
16. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
17. Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.
Corm S; Biggio V; Roche-Lestienne C; Laï JL; Yakoub-Agha I; Philippe N; Nicolini FE; Facon T; Preudhomme C
Leukemia; 2005 Nov; 19(11):1991-2. PubMed ID: 16151468
[No Abstract] [Full Text] [Related]
18. CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?
Goldman J
Lab Hematol; 2004; 10(3):181-4. PubMed ID: 15529444
[No Abstract] [Full Text] [Related]
19. Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia.
Yamamoto K; Yakushijin K; Nishikawa S; Minagawa K; Katayama Y; Shimoyama M; Matsui T
Cancer Genet Cytogenet; 2008 May; 183(1):77-81. PubMed ID: 18474303
[TBL] [Abstract][Full Text] [Related]
20. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
[No Abstract] [Full Text] [Related]
[Next] [New Search]
